GeoVax Labs (GOVX) EBITDA Margin (2010 - 2025)
GeoVax Labs (GOVX) posted quarterly EBITDA Margin of 635.81% for Q2 2025, up 104780.0% year-over-year from N/an in Q2 2024, and down 92.54% quarter-over-quarter from 330.22% in Q1 2025.
GeoVax Labs (GOVX) EBITDA Margin (2010 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported EBITDA Margin for 15 consecutive years, with 635.81% the latest figure, recorded in Q2 2025.
- In Q2 2025, EBITDA Margin rose 104780.0% year-over-year to 635.81%; the TTM figure through Jun 2026 stood at 2425.95% (down 201861.0% YoY), while the FY2025 annual figure was 869.34%, down 23351.0% from the prior year.
- EBITDA Margin fell to 635.81% in Q2 2025 per GOVX's latest filing, from 330.22% in the prior quarter.
- Across five years, EBITDA Margin topped out at 209.88% in Q3 2024 and bottomed at 8331.46% in Q4 2021.
- Historically, EBITDA Margin has averaged 2483.22% across 4 years, with a median of 1550.06% in 2021.
- Annual changes were most pronounced in 2021 — EBITDA Margin sank 780007 bps — and 2025, when it soared 104780 bps.
- GeoVax Labs' EBITDA Margin stood at 8331.46% in 2021, then jumped by 64 bps to 2978.24% in 2022, then jumped by 68 bps to 965.32% in 2024, then surged by 34 bps to 635.81% in 2025.
- Business Quant data shows GOVX's EBITDA Margin at 635.81% in Q2 2025, 330.22% in Q1 2025, and 965.32% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 19.75% |
| 10 | GeoVax Labs | 2.86 Mn | -287,884.91 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -635.81% |
| Mar 31, 2025 | -330.22% |
| Dec 31, 2024 | -965.32% |
| Sep 30, 2024 | -209.88% |
| Jun 30, 2024 | -1,683.61% |
| Mar 31, 2022 | -2,978.24% |
| Dec 31, 2021 | -8,331.46% |
| Sep 30, 2021 | -6,416.06% |
| Jun 30, 2021 | -1,865.09% |
| Mar 31, 2021 | -1,416.52% |
| Dec 31, 2020 | -531.39% |
| Sep 30, 2020 | -105.02% |
| Jun 30, 2020 | -101.70% |
| Mar 31, 2020 | -83.15% |
| Dec 31, 2019 | -220.13% |
| Sep 30, 2019 | -127.83% |
| Jun 30, 2019 | -311.49% |
| Mar 31, 2019 | -192.61% |
| Dec 31, 2018 | -211.94% |
| Sep 30, 2018 | -191.02% |